Cited by 1,790SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmune responses and vaccinations

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Open access

Rydyznski Moderbacher, Carolyn, Ramirez, Sydney I., Dan, Jennifer M., Grifoni, Alba, Hastie, Kathryn M., Weiskopf, Daniela, Belanger, Simon, Abbott, Robert K., Kim, Christina, Choi, Jinyong, Kato, Yu, Crotty, Eleanor G., Kim, Cheryl, Rawlings, Stephen A., Mateus, Jose, Tse, Long Ping Victor, Frazier, April, Baric, Ralph, Peters, Bjoern, Greenbaum, Jason, Saphire, Erica Ollmann, Smith, Davey M., Sette, Alessandro, Crotty, Shane·2020·Cell

DOI 10.1016/j.cell.2020.09.038PMC PMC7494270

Open this paper in CoChat — free account

Abstract

Limited knowledge is available on the relationship between antigen-specific immune responses and COVID-19 disease severity. We completed a combined examination of all three branches of adaptive immunity at the level of SARS-CoV-2-specific CD4 + and CD8 + T cell and neutralizing antibody responses in acute and convalescent subjects. SARS-CoV-2-specific CD4 + and CD8 + T cells were each associated with milder disease. Coordinated SARS-CoV-2-specific adaptive immune responses were associated with milder disease, suggesting roles for both CD4 + and CD8 + T cells in protective immunity in COVID-19. Notably, coordination of SARS-CoV-2 antigen-specific responses was disrupted in individuals ≥ 65 years old. Scarcity of naive T cells was also associated with aging and poor disease outcomes. A parsimonious explanation is that coordinated CD4 + T cell, CD8 + T cell, and antibody responses are protective, but uncoordinated responses frequently fail to control disease, with a connection between aging and impaired adaptive immune responses to SARS-CoV-2.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2020.09.038

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Graphical abstract CC BY · PubMed Central

Figure S1 SARS-CoV-2 Antibody Responses, Related to Figure 1 (A) Frequency of Peak Disease Severity (1-10) for acute and convalescent COVID-19. (B-J) Plasma ELISA curves for SARS-CoV-2 spike RBD (B) IgG, (C) IgA, (D) IgM; SARS-CoV-2 Spike (E) IgG, (F) IgA, (G) IgM; and SARS-CoV-2 Nucleocapsid (N) protein (H) IgG, (I) IgA, and (J) IgM. C92 and C98 are representative acute donors. Grey lines = all other COVID-19 samples. The dotted line indicates LOD. (K) Correlation of Spike IgA with RBD IgA. (L) Correlation of N IgA with Spike IgA. (M) Correlation of PSV neutralizing titer with live neutralizing titer. (N) PSV titration curves. C92 and C98 are representative acute COVID-19 donors. Grey lines = all other COVID-19 samples. (O, P) PSV neutralizing titer correlates with RBD IgA (O) and RBD IgG+IgA (P). In (K-M) and (O-P), white dots = all COVID-19 (acute and convalescent). Statistics reported for all COVID-19 cases.CC BY · PubMed Central

Figure 1 SARS-CoV-2 Antibody Responses in COVID-19 Subjects (A–C) Plasma antibody titers to SARS-CoV-2 S RBD (A) IgG, (B) IgA, and (C) IgM, divided into unexposed n = 15, acute (Ac) n = 28, and convalescent (Co) n = 15. (D) SARS-CoV-2 RBD IgG correlates with RBD IgA. (E–G) Plasma ELISA titers to SARS-CoV-2 S (E) IgG, (F) IgA, and (G) IgM. (H) S IgG correlation with RBD IgG. (I–K) Plasma ELISA titers to SARS-CoV-2 Nucleocapsid (N) protein (I) IgG, (J) IgA, and (K) IgM. (L) N IgG correlation with S IgG. (M) Pseudovirus (PSV) neutralizing antibody titers in unexposed, acute, and convalescent COVID-19 samples. (N) PSV neutralizing antibody titers correlated with RBD IgG titers. (O and P) Both (O) RBD IgG and (P) PSV neutralizing Ab titers were detectable in most acute and all convalescent COVID-19 cases at all time points tested. The dotted line indicates LOD. Geometric mean titers with geometric SDs are indicated. Acute (Ac) = Red, Convalescent (Co) = black, Unexposed = gray. White = all COVID-19 (acute and convalescent). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, NS = not significant. See also Figure S1.CC BY · PubMed Central

Figure 2 SARS-CoV-2-Specific CD4+ T Cell Responses (A) Representative flow cytometry gating of AIM+ (OX40+surfaceCD40L+) CD4+ T cells. (B) Percentage of background subtracted SARS-CoV-2-specific total CD4+ T cells quantified by AIM after stimulation with MP_R (Non-Spike), S (Spike), M (Membrane), or N (Nucleocapsid) peptide pools in unexposed (n = 15), acute COVID-19 (n = 30) and convalescent COVID-19 (n = 15). (C and D) Percentage of background subtracted combined MP_R, S, M, and N SARS-CoV-2-specific CD4+ T cells by AIM assay by (C) cohort and (D) by days PSO. Combined AIM responses were calculated as the sum of the CD4+ AIM response to background-subtracted individual peptide megapools. Statistics in (D) are reported for unexposed, convalescent, and acute samples. (E and F) ICS of SARS-CoV-2-specific CD4+ T cells quantified by co-expression of (E) CD40L+IFNγ+ or (F) CD40L+IL-2+ after stimulation with SARS-CoV-2 peptide pools in unexposed (n = 8), acute COVID-19 (n = 14) and convalescent COVID-19 samples (n = 11). (G and H) Cytokines IFNγ (G) and IL-2 (H) in the supernatants after stimulation with SARS-CoV-2 or CMV peptide pools in unexposed (n = 15), acute COVID-19 (n = 22), convalescent COVID-19 (n = 15), and CMV+ controls (n = 23). The black dotted line delineates background signal as determined by the unexposed controls. (I) Representative flow cytometry of SARS-CoV-2-specific (OX40+CD40L+) CD4+ T cells (blue dots) overlaid on total CD4+T cells (black dots). (J) Percentage of SARS-CoV-2-specific cTFH cells in acute COVID-19 (n = 22) or convalescent COVID-19 (n = 15) samples that had a positive total CD4+ AIM response (> 0.04%) following stimulation with the SARS-CoV-2 S megapool (MP), or the total non-antigen-specific CXCR5+ CD4+ T cells in unexposed controls (n = 15, gray dots) (median displayed). (K) Representative fluorescence-activated cell sorting (FACS) plots of CXCR3 and CCR6 staining in total cTFH (CXCR5+CD4+ cells) in unexposed donors or S-specific AIM+ (OX40+CD40L+) CD4+ T cells in acute and convalescent donors. (L and M) Frequency of (L) CXCR3 and/or CCR6 expressing S-specific AIM+ cells out of total CD4+ T cells in acute or convalescent samples or non-antigen-specific CXCR5+CD4+ cTFH in unexposed samples (n = 15) and (M) CXCR5+ S-reactive AIM+ cells out of total CD4+ T cells in acute donors (n = 26 samples) or convalescent donors (n = 15 samples). Unless otherwise stated, the black dotted line indicates LOD; the green dotted line demarcates marginal responses as determined by unexposed donor responses. Pink dots denote samples where two or more peptide pools were not run due to cell numbers. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, NS = not significant. See also Figure S2, Table S4, and Table S5.CC BY · PubMed Central

Figure S2 SARS-CoV-2-Specific CD4+ T Cell Responses, Related to Figure 2 (A) Gating strategy for identification of SARS-CoV-2-antigen-specific CD4+ T cells. (B) % of OX40+4-1BB+ CD4+ T cells specific for SARS-CoV-2 MP_R, S, M, N peptide megapools by AIM (C) Combined % Ox40+4-1-BB+ CD4+ T cells across all SARS-CoV-2 peptide megapools by AIM. The black dotted line indicates LOD; the green dotted line demarcates marginal responses as determined by unexposed donor responses. Pink dots denote samples where two or more peptide pools were not run due to cell numbers. (D-F) Amount (pg/mL) of (D) IL-5 (E), IL-13 (F), and IL-17 in the AIM supernatants after stimulation with MP_R, S, M, N, and CMV peptide pools. The black dotted line delineates background signal as determined by the unexposed controls. Acute (Ac) = Red, Convalescent (Co) = black, Unexposed (Unexp) = gray. ∗p < 0.05, ∗∗p < 0.01, NS = not significant.CC BY · PubMed Central

Figure 3 SARS-CoV-2-Specific CD8+ T Cell Responses (A) Sample flow cytometry gating of AIM (CD69+4-1BB+) CD8+ T cells. (B) Percentage of background subtracted SARS-CoV-2-specific total CD8+ T cells via AIM assay after stimulation with CD8_A/B, MP_R (Non-Spike), S (Spike), M (Membrane), N (Nucleocapsid) peptide pools in unexposed (n = 15), acute COVID-19 (n = 30) and convalescent COVID-19 (n = 15). (C and D) Percentage of background subtracted combined CD8-A/B, R, S, M, and N SARS-CoV-2-specific total CD4+ T cells by AIM assay (C) by cohort and (D) by days PSO. Combined AIM responses were calculated as the sum of the CD8+ AIM response to background-subtracted individual peptide megapools. Statistics in (D) are reported for unexposed, acute, and convalescent samples. (E) Quantitation of IFNγ in supernatants after stimulation with peptide pools unexposed (n = 15), acute COVID-19 (n = 21), and convalescent COVID-19 (n = 15). The black dotted line delineates background signal as determined by the unexposed controls. (F) Percentage of background subtracted SARS-CoV-2-specific total CD8+ T cells quantified by expression of IFNγ+ by ICS. (G) Representative flow cytometry gating of IFNγ+GzmB+ CD8+ T cells in acute and convalescent COVID-19 samples. (H) Percentage of IFNγ+ CD8+ T cells expressing granzyme B (GzmB), TNFα, or IL10 by ICS in unexposed (n = 8), acute COVID-19 (n = 14) and convalescent COVID-19 (n = 11). Unless otherwise stated, the black dotted line indicates LOD; the green dotted line demarcates marginal responses as determined by unexposed donor responses. Pink dots denote samples where two or more peptide pools were not run due to cell numbers. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, NS = not significant. See also Figure S3, Table S4, and Table S5.CC BY · PubMed Central

Figure S3 SARS-CoV-2-Specific CD8+ T Cell Responses, Related to Figure 3 (A) Gating strategy for identification of SARS-CoV-2-antigen-specific CD8+ T cells. (B) Percentage of background subtracted SARS-CoV-2-specific total CD8+ T cells quantified by co-expression of IFNg and granzyme B (GzmB) by ICS in unexposed (n = 8), acute COVID-19 (n = 11) and convalescent COVID-19 (n = 11). The black dotted line indicates LOD. Acute (Ac) = Red, Convalescent (Co) = black, Unexposed (Unexp) = gray. ∗p < 0.05, ∗∗p < 0.01. NS = not significant.CC BY · PubMed Central

Figure 4 Coordinated Adaptive Immune Responses to SARS-CoV-2 (A) Correlation of SARS-CoV-2-specific CD4+ T cells and RBD IgG. (B) Correlation of SARS-CoV-2-specific CD8+ T cells and RBD IgG. (C) Correlation of SARS-CoV-2-specific CD4+ and CD8+ T cells. (D) PSV neutralizing antibody titers over time for acute COVID-19 subjects with paired blood samples. Open circles denote other acute COVID-19 samples. Unexposed controls (n = 15), acute COVID-19 (n = 26), and convalescent COVID-19 (n = 15). The black dotted line indicates LOD; the green dotted line demarcates marginal responses as determined by unexposed donor responses. Pink dots denote samples where two or more peptide pools were not run due to cell numbers. (E) Association between SARS-CoV-2 PSV-neutralizing antibodies and peak disease severity. (F and G) Association between (F) SARS-CoV-2-specific CD4+ T cells and (G) SARS-CoV-2-specific CD8+ T cells (“Low” < 0.1%, “High” > 0.1% combined AIM+) and COVID-19 peak disease severity. (H) Association between ADIM score and COVID-19 peak disease severity. Acute COVID-19 samples (n = 26) and convalescent COVID-19 samples (n = 26). Statistics for (A–C) are reported for unexposed, convalescent, and acute samples. ∗p < 0.05, ∗∗p < 0.01, NS = not significant. See also Figure S4 and Data S1.CC BY · PubMed Central

Figure S4 Coordinated Adaptive Immune Responses, Related to Figure 4 (A-B) PSV neutralizing titer (A) and (B) percentage of SARS-CoV-2-specific TFH cells in samples that had a positive total CD4+ AIM response (> 0.04%) following stimulation with the SARS-CoV-2 S MP, or the total CXCR5+ CD4+ T cells in unexposed controls in additional unexposed donors (n = 12) and convalescent COVID-19 donors (n = 11). (C-D) Flow cytometry of AIM+ CD4+ T cell response (C) and AIM+ CD8+ T cells response (D) in donor C4844. (E) Frequency of ADIM observed in the cohort. (F) Correlation of SARS-CoV-2-specific total CD4+ T cells by OX40+CD40L+ AIM assay and days PSO, stratified into Immunotypes. Statistics are reported for unexposed, convalescent and acute samples. (G) Frequency of ADIM by gender. (H-I) Combined CD4+ AIM data based on day PSO from Fig. 2D and 3D with responses labeled for specific donors of interest. Statistics in (H-I) are reported for unexposed, convalescent and acute samples. The black dotted line indicates LOD; the green dotted line demarcates marginal responses as determined by unexposed donor responses. Pink dots denote samples where two or more peptide pools were not run due to cell numbers. NS = not significant, ∗∗∗p < 0.001, geometric mean with geometric SD displayed in S4A, median displayed in S4B.CC BY · PubMed Central

Figure S5 Plasma Cytokines and Immunophenotyping, Related to Figure 5 (A-M) Quantitation of plasma cytokine levels from acute (n = 24) and unexposed (n = 15) donors: (A) CXCL10, (B) IL-8, and (C) IL-6. (D) IL-1b, (E) TNFa, (F) IFNl1, (G) IL12p70, (H) IFNa2, (I) IFNl2, (J) GM-CSF, (K) IFNb, (L) IL-10, (M) IFNg. (N) Correlation of CD3-CD19- PBMCs and peak disease severity. Statistics are reported for convalescent and acute samples. (O-P) Correlation of (O) activated CD4 T cells with combined AIM+ CD4 T cells and (P) activated CD8 T cells with combined AIM+ CD8 T cells across all donors. Statistics are reported for unexposed, convalescent and acute samples. (Q) Correlation of (CD38hiCD20-CD19+) plasmablasts with RBD IgG titers. Statistics are reported for unexposed and acute samples. (R) Gating strategies for plasmablasts and T cell subtypes. The black dotted line indicates LOD; the green dotted line demarcates marginal responses as determined by unexposed donor responses. Pink dots denote samples where two or more peptide pools were not run due to cell numbers. Acute (Ac) = Red, Convalescent = black, Unexposed (Unexp) = gray. ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, NS = not significant.CC BY · PubMed Central

Figure S6 Correlations of the Immune Response with Disease Severity in COVID-19 Donors, Related to Figure 6 Correlogram of all COVID-19 cases. Spearman R values are shown from red (−1.0) to blue (1.0); r values are indicated by color and square size. Peak COVID-19 disease severity (“Peak disease”) is the bottom row. Additional information on feature names are described in the STAR Methods. Blank fields with dots indicate lack of signal. p values are indicated by white asterisks. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.CC BY · PubMed Central

Figure 5 Associations of Adaptive Immune Response Features with COVID-19 Severity (A) Correlogram of acute COVID-19 donors. Spearman rank order correlation values (r) are shown from red (−1.0) to blue (1.0); r values are indicated by color and square size. Blank fields with black dots indicate lack of signal. p values are indicated by white asterisks. The teal triangle denotes SARS-CoV-2 antibody features, magenta triangle denotes SARS-CoV-2-specific CD4+ T cells features, and orange triangle denotes SARS-CoV-2-specific CD8+ T cell features. Purple rectangles denote coordinated adaptive immune response features. The dark green line denotes select inflammatory cytokines. Peak COVID-19 disease severity (“Peak disease”) is the bottom row. Additional information on feature names are described in the STAR Methods. (B) Correlation of Ki67+CD38+HLA-DR+ CD4+ T cells (as percentage of total CD4+ T cells) with SARS-CoV-2-specific (combined AIM+) CD4+ T cells. (C) Correlation of Ki67+CD38+HLA-DR+ CD8+ T cells (as percentage of total CD8+ T cells) with SARS-CoV-2-specific (combined AIM+) CD8+ T cells. (D) Correlation of activated (ICOS+PD-1hi) TFH cells (as percentage of total CD4+ T cells) with SARS-CoV-2-specific (combined AIM+) TFH (CXCR5+CD4+) cells. (E) Correlation of SARS-CoV-2 PSV-neutralizing antibody titer and percentage plasmablasts (CD38hiCD20- of CD19+ B cells). Unexposed controls (n = 15), acute COVID-19 (n = 26) displayed. Statistics reported for (B–E) are reported for unexposed and acute donors. The black dotted line indicates LOD; the green dotted line demarcates marginal responses as determined by unexposed donor responses. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. See also Figure S5, Table S3, and Data S1.CC BY · PubMed Central

Figure 6 Association of Age and Naive T Cells with COVID-19 Severity (A and B) Correlograms of acute donors < 65 years (A) and ≥ 65 years (B). As in Figure 5, Spearman r correlation values are shown from red (−1.0) to blue (1.0); r values are indicated by color and square size. Blank fields with dots indicate lack of signal. p values are indicated by white asterisks. Also, as in Figure 5, the teal triangle denotes SARS-CoV-2 antibody features, magenta triangle denotes SARS-CoV-2-specific CD4+ T cells features, and orange triangle denotes SARS-CoV-2-specific CD8+ T cell features. Purple rectangles denote coordinated adaptive immune response features. Peak COVID-19 disease severity (“Peak disease”) is the bottom row. Select inflammatory cytokines are labeled with a dark green line. (C) Correlation of age and peak disease severity. Statistics for full dataset shown are in black; statistics for acute COVID-19 cases are in red. (D) Correlation of naive CD4+ T cells (as percentage of total CD4+ T cells) with age. Statistics for full dataset are shown in black; statistics for all COVID-19 cases (convalescent and acute) are in blue; statistics for acute COVID-19 cases are in red. (E) Correlation of naive CD4+ T cells (as percentage of total CD4+ T cells) and peak disease severity. Statistics for all COVID-19 cases (convalescent and acute) are in blue; statistics for acute COVID-19 cases are in red. (F) Correlation of naive CD8+ T cells (as percentage of total CD8+ T cells) with age. Statistics for full dataset are shown in black; statistics for all COVID-19 cases (convalescent and acute) are in blue; statistics for acute COVID-19 cases are in red. (G) Correlation of naive CD8+ T cells (as percentage of total CD8+ T cells) and peak disease severity. Statistics for all COVID-19 cases (convalescent and acute) are in blue; statistics for acute COVID-19 cases are in red. Unexposed controls in gray (n = 67), convalescent COVID-19 in black (n = 15), acute COVID-19 in red (n = 26) displayed. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. See also Figures S6 and S7, Table S3, and Data S1.CC BY · PubMed Central

Figure S7 Uncoordinated Adaptive Immunity in the Elderly, Related to Figures 6 and 7 (A-B) Correlograms of all acute COVID-19 cases age < 75 (A) and ≥ 75 (B). Spearman R values are shown from red (−1.0) to blue (1.0). Blank fields with dots indicate lack of signal. (C) Correlogram of curated markers of adaptive immune responses in acute COVID-19 subjects (top) and all COVID-19 subjects (bottom). Spearman r correlation values are shown from red (−1.0) to blue (1.0). ∗p < 0.05, ∗∗p < 0.001, ∗∗∗p < 0.0001. Thick black squares outlining a field indicate adjusted FDR < 0.05. (D-E) Gating strategies for (D) naive CD8+ and (E) CD4+ T cells for acute and donors < 75 years old and ≥75 years old, and convalescent donors. (F) Secreted IFNg (pg/mL) after SARS-CoV-2 CD8A/B MP stimulation, versus peak COVID-19 disease severity, acute samples (n = 21). Statistics in (F) are reported for acute samples (shown in red). ∗p < 0.05, ∗∗p < 0.001, ∗∗∗p < 0.0001.CC BY · PubMed Central

Figure 7 Associations of COVID-19-Specific CD4 and CD8 T Cell Responses and Disease Severity (A) Frequency of IFNγ+ CD8+ T cells in response to CD8A/B MP ICS, versus peak COVID-19 disease severity, acute donors (n = 11 samples). Dotted line indicates LOD. (B–D) Associations between peak COVID-19 disease severity and number per million PBMC of (B) AIM+ CD8+ T cells (CD69+4-1BB+CD8+), (C) AIM+ CD4+ T cells (OX40+surfaceCD40L+), or (D) AIM+ cTFH cells (OX40+CD40L+CXCR5+CD4+) across all SARS-CoV-2 peptide-specific MPs, acute samples (n = 26), and convalescent samples (n = 15). (E and F) Frequency of (E) CXCR3-CCR6+ S-specific (AIM+) CD4+ T cells and (F) CXCR5+CXCR3-CCR6+ S-specific (AIM+) cTFH CD4+ T cells versus peak disease severity, acute samples (n = 26), and convalescent samples (n = 15). Dotted line denotes LOD. Statistics for acute COVID-19 cases are in red; statistics for all COVID-19 cases (convalescent and acute) are in black. See also Figure S7 and Data S1.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-Infected pneumonia in Wuhan, China
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148 · cited 2×
“…titers were associated with protection against SARS-CoV-2 in non-human primate infection and rechallenge studies (Chandra-shekar et al., 2020; Gao et al., 2020), as well as in three candidate COVID-19 vaccine studies in non-human primates (Gao et al., 2020; Wang et al., 2020c; Yu et al., 2020).”
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254 · cited 2×
“…increased rates of severe and fatal disease among older individuals (> 65 years old) (Docherty et al., 2020; Grasselli et al., 2020) and those with pre-existing medical conditions like cardiovascular disease, obesity, and type 2 diabetes mellitus (Docherty et al., 2020; Richardson et al., 2020).”
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy
Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., et al. (2020) · JAMA · doi:10.1001/jama.2020.5394 · Cited by 5,469 · cited 3×
“…and many fatalities occur, with increased rates of severe and fatal disease among older individuals (> 65 years old) (Docherty et al., 2020; Grasselli et al., 2020) and those with pre-existing medical conditions like cardiovascular disease, obesity, and type 2 diabetes mellitus (Docherty…”
Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Héry-Arnaud, G., Berre, R. L., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 5,008
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750 · cited 1×
“001; Figures S5A–S5C) and correlated with disease severity (Figure 5A), consistent with large cohort studies of plasma cytokines (Chen et al., 2020; Laing et al., 2020; Mathew et al., 2020; Yang et al., 2020).”
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222 · cited 2×
“Elevated innate immune cytokines detected in peripheral blood including interleukin (IL)-1, IL-6, IL-8, or C-X-C Motif Chemokine Ligand 10 (CXCL10) have been associated with severe or fatal COVID-19 (Blanco-Melo et al., 2020; Laing et al., 2020; Lucas et al., 2020; Vabret et al., 2020; Del Valle et al., 2020).”

Show all 77 references

Sorted by citations

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
“Neutralizing antibodies have generally not correlated with lessenedCOVID-19disease severity (5, 19,20), which was also observed for Middle Eastern respiratory syndrome (MERS), causedbyMERSCoV (21).”
BackgroundMethodResultInfluentialSelf-citation
Adaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860
“Notably, frequencies of RBD (and Spike) memory B cells increased over time, with more RBDmemory B cells at 6 months PSO than at 1 month PSO (Dan et al., 2021; Gaebler et al., 2020), consistent with observations at 3 months PSO (Rodda et al., 2021).”
InfluentialSelf-citation
The T cell immune response against SARS-CoV-2
Moss, P. A. H. (2022) · Nature Immunology · doi:10.1038/s41590-021-01122-w · Cited by 1,243
SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron
Tarke, A., Coelho, C. H., Zhang, Z., Dan, J. M., Yu, E. D., Methot, N., Bloom, N. I., Goodwin, B., Phillips, E., Mallal, S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.015 · Cited by 858
“SARS-CoV-2 serology and PSV neutralization assay SARS-CoV-2 serology was performed for all plasma samples collected as previously described(Rydyznski Moderbacher et al., 2020).”
Self-citation

See all 1,790

Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Moderbacher et al.
Ramirez, S. (2020) · Data Archiving and Networked Services (DANS) · doi:10.17632/n66n5pj4f6
Impaired Priming of SARS-CoV-2-Specific Naive CD8+ T Cells in Older Subjects
Gallerani, E., Proietto, D., Dallan, B., Campagnaro, M., Pacifico, S., Albanese, V., Marzola, E., Marconi, P., Caputo, A., Appay, V., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693054 · Cited by 28
Aging and inflammation limit the induction of SARS-CoV-2–specific CD8+ T cell responses in severe COVID-19
Autaa, G., Papagno, L., Nogimori, T., Boizard-Moracchini, A., Korenkov, D. A., Roy, M., Suzuki, K., Masuta, Y., White, E., Llewellyn‐Lacey, S., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.180867 · Cited by 9
Ageing Curtails the Diversity and Functionality of Nascent CD8+ T Cell Responses against SARS-CoV-2
Proietto, D., Dallan, B., Gallerani, E., Albanese, V., Llewellyn‐Lacey, S., Price, D. A., Appay, V., Pacifico, S., Caputo, A., Nicoli, F., et al. (2023) · Vaccines · doi:10.3390/vaccines11010154 · Cited by 9
Longitudinal analyses reveal age-specific immune correlates of COVID-19 severityPreprint
Lewis, S. A., Sureshchandra, S., Zulu, M. Z., Doratt, B. M., Pinski, A. N., Curtis, M., Jankeel, A., Ibraim, I. C., Rhoades, N. S., Jiang, X., et al. (2021) · medRxiv · doi:10.1101/2021.01.25.21250189 · Cited by 4
Age-related decline of de novo T cell responsiveness as a cause of COVID-19 severity
Nicoli, F., Solís-Soto, M. T., Paudel, D., Marconi, P., Gavioli, R., Appay, V., & Caputo, A. (2020) · GeroScience · doi:10.1007/s11357-020-00217-w · Cited by 27
The effect of age on the magnitude and longevity of Th1‐directed CD4 T‐cell responses to SARS‐CoV ‐2
Nattrass, R. G., Krafft, L., Zjablovskaja, P., Schuster, M., Kasmapour, B., Sarisoy, C., Minich, J., Bach, E., & Streeck, H. (2022) · Immunology · doi:10.1111/imm.13475 · Cited by 4
Effects of aging and inflammation on antigen-specific CD8+ T-cell responses that protect against severe disease following SARS-CoV-2 infection
Nogimori, T., & Yamamoto, T. (2025) · Uirusu · doi:10.2222/jsv.75.47
The effectiveness of the immune responses to SARS-CoV-2
Salih, B. A. (2022) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000306
Age-related peculiarities of antibody-mediated humoral immune response following SARS-CoV-2 infection
Movsisyan, M., Harutyunyan, H. A., Kh, M., Kasparova, I., Hakobyan, A., & Yenkoyan, K. B. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112735 · Cited by 3

Authors: Rydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S., Abbott, R. K., Kim, C., Choi, J., Kato, Y., Crotty, E. G., Kim, C., Rawlings, S. A., Mateus, J., Tse, L. P. V., Frazier, A., Baric, R., Peters, B., Greenbaum, J., Saphire, E. O., Smith, D. M., Sette, A., & Crotty, S.
Affiliations: La Jolla Institute for Immunology (US)
University of California San Diego (US)
University of North Carolina at Chapel Hill (US)
Corresponding author: Sette, Alessandro
Crotty, Shane
ORCID: Ramirez, Sydney I.
Dan, Jennifer M.
Grifoni, Alba
Hastie, Kathryn M.
Weiskopf, Daniela
Abbott, Robert K.
Kim, Christina
Choi, Jinyong
Kato, Yu
Kim, Cheryl
Rawlings, Stephen A.
Mateus, Jose
Tse, Long Ping Victor
Frazier, April
Baric, Ralph
Peters, Bjoern
Greenbaum, Jason
Saphire, Erica Ollmann
Smith, Davey M.
Sette, Alessandro
Crotty, Shane
Venue: Cell
Publisher: Elsevier BV
Published: 2020-11
Volume: 183
Issue: 4
Pages: 996-1012.e19
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2020.09.038
PMC: PMC7494270
OpenAlex: W3084879098
Cited by: 1,790
References: 77
Citations by year: 2026: 54 · 2025: 144 · 2024: 180 · 2023: 288 · 2022: 543 · 2021: 517 · 2020: 62
FWCI: 46.45
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Cell (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: Bill and Melinda Gates Foundation (INV-006133)
National Institute of Allergy and Infectious Diseases (U19 AI118626, AI100625, 75N9301900065, AI142742, AI145762, AI135078)
National Institutes of Health
Pontificia Universidad Javeriana
University of California, San Diego
Departamento Administrativo de Ciencia, Tecnología e Innovación
Wellcome
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Keywords: SARS-CoV-2, COVID-19 pandemic, CD4+ T cells, CD8+ T cells, neutralizing antibodies, disease severity, age, naive T cells, immunosenescence
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, Acute Disease, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Antigens, Viral, Female, Humans, Male, Middle Aged, Pneumonia, Viral, Severity of Illness Index, CD4-Positive T-Lymphocytes, Cytokines, Coronavirus Infections, CD8-Positive T-Lymphocytes, Young Adult, Adaptive Immunity, Antibodies, Neutralizing, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks